CORRECTION: Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and person/companies closely associated with these

Insiders' dealing



CORRECTION TO ANNOUNCEMENT ON INSIDERS' DEALING OF 14.11.2007
- AA Consult Aps has exercised 250 preemptive rights instead of 300 as
previously announced corresponding to a market value of DKK 70,000. 



Report of transactions with shares and related securities of NeuroSearch by
persons discharging managerial responsibilities and person/companies closely
associated with these 

Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch
A/S (NEUR.CO) shall make public transactions with shares and related securities
of NeuroSearch A/S by persons discharging managerial responsibilities and
persons/companies closely associated with these. 

Name: Allan Andersen 
Reason: Board member
Issuer and ID code / ISIN: NeuroSearch A/S / DK0060098408
Transaction: Sale of preemptive rights
Trading date: 13 November 2007
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 22,742
Market value (DKK): 181,936

Name: AA Consult ApS
Reason: Related to Allan Andersen, Board member
Issuer and ID code / ISIN: NeuroSearch A/S / DK0060098325
Transaction: Purchase/exercise of preemptive rights 
Trading date: 13 November 2007
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 250
Market value (DKK): 70,000

Name: AA Consult ApS
Reason: Related to Allan Andersen, Board member
Issuer and ID code / ISIN: NeuroSearch A/S / DK0060098408
Transaction: Sale of preemptive rights
Trading date: 13 November 2007
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 7,274
Market value (DKK): 58,192

Name: Jørgen Drejer 
Reason: Member of the executive management
Issuer and ID code / ISIN: NeuroSearch A/S / DK0060098408
Transaction: Sale of preemptive rights
Trading date: 12 November 2007
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 79,080
Market value (DKK): 644,502
 

Name: Frank Wätjen 
Reason: Member of the executive management
Issuer and ID code / ISIN: NeuroSearch A/S / DK0060098408
Transaction: Sale of preemptive rights
Trading date: 12 November 2007
Market: The OMX Nordic Exchange Copenhagen A/S
Number (pcs): 40,118
Market value (DKK): 341,003



Contact person: 
Anita Milland, Vice President, CFO, telephone:  +45 2016 3432




NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the Company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD
(Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in
schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar
disorder and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for
the treatment of various CNS diseases - both (Phase I) in collaboration with
Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug
candidates and holds equity interests in several biotech companies.